Venetoclax/Venetoclax Price Comparison

Venetoclax/Venetoclax is a selective, potent B-cell lymphoma-BCL-2) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) with comorbidities that preclude chemotherapy. Several other hematologic malignancies are currently being evaluated. BCL-2 is overexpressed in several cancers and inhibits programmed cell death by protecting cells from various pro-apoptotic stimuli. Venetoclax inhibits BCL-2 signaling, thereby inducing apoptosis.

In China, the original drug of Venecla is already on the market and provides patients with a wide range of specifications to choose from. The price of the medicine varies depending on the specifications, with each box selling for approximately 1,000 to 4,000 yuan. This drug has also been included in the Class B medical insurance system, but medical insurance reimbursement is limited to patients diagnosed with adult acute myeloid leukemia. Those who do not meet the conditions can only purchase it at their own expense.

For those patients who consider purchasing drugs from overseas, the price of the Turkish version of the original drug is relatively high, with the specification of 100mg*112 tablets costing more than 10,000 yuan per box. In addition, there are also generic drug options of Veneclax on the market, and the main ingredients of these drugs are basically the same as the original drugs. Common manufacturers may include Laos Lucius Pharmaceuticals, Bangladesh Yaopin International, etc. Take the generic drugs produced by Laos pharmaceutical factories as an example. Each box contains 120 100mg tablets, and the price is about 2,000 yuan. The price of drugs may be affected by exchange rate changes. Compared with original drugs, generic drugs are more affordable.